Old and new challenges in Chagas disease

The Lancet Infectious Diseases

Volumn 15, Issue 11, 2015, Pages 1347-1356

  Pérez Molina, Jose A ^a   Perez, Angela Martinez ^a   Norman, Francesca F ^a   Monge Maillo, Begoña ^a   López Vélez, Rogelio ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN G ANTIBODY; NIFURTIMOX; PREDNISONE; RITUXIMAB; VINCRISTINE; PROTOZOAL DNA; PROTOZOON ANTIBODY;

ADULT; ANTIBODY TITER; BLOOD TRANSFUSION; BOLIVIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CHAGAS DISEASE; DRUG MEGADOSE; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOFLUORESCENCE TEST; MEDICATION COMPLIANCE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RURAL AREA; SPAIN; TREATMENT DURATION; TRYPANOSOMA CRUZI; BLOOD; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIGRANT; NEGLECTED DISEASES; PATHOLOGY; POLYMERASE CHAIN REACTION;

ADULT; ANTIBODIES, PROTOZOAN; CHAGAS DISEASE; DNA, PROTOZOAN; EMIGRANTS AND IMMIGRANTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; NEGLECTED DISEASES; POLYMERASE CHAIN REACTION; SPAIN; TRYPANOSOMA CRUZI;

EID: 84945482639     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00243-1     Document Type: Review

References (91)

1. Stevens L, Dorn PL, Schmidt JO, Klotz JH, Lucero D, Klotz SA The vectors of Chagas. Adv Parasitol 2011, 75:169-192.
2. Rassi A, Rassi A, Marin-Neto JA Chagas disease. Lancet 2010, 375:1388-1402.
3. Howard EJ, Xiong X, Carlier Y, Sosa-Estani S, Buekens P Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysis. BJOG 2014, 121:22-23.
4. Bern C, Verastegui M, Gilman RH, et al. Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia. Clin Infect Dis 2009, 49:1667-1674.
5. Lescure F-X, Le Loup G, Freilij H, et al. Chagas disease: changes in knowledge and management. Lancet Infect Dis 2010, 10:556-570.
6. Pérez-Molina J, Norman F, López-Vélez R Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment. Curr Infect Dis Rep 2012, 14:263-274.
7. Pinazo M-J, Thomas CM, Bua J, et al. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Rev Anti Infect Ther 2014, 12:479-496.
8. Organización Panamericana de la salud (OPS/OMS). Estimación cuantitativa de la Enfermedad de Chagas en las Américas. OPS/HDM/CD/425-06. Montevideo, Uruguay. 2006.
9. Schmunis GA, Yadon ZE Chagas disease: a Latin American health problem becoming a world health problem. Acta Tropica 2010, 115:14-21.
10. Martinez-Perez A, Norman FF, Monge-Maillo B, Perez-Molina JA, Lopez-Velez R An approach to the management of Trypanosoma cruzi infection (Chagas disease) in immunocompromised patients. Expert Rev Anti Infect Ther 2014, 12:357-373.
11. Perez-Molina JA Management of Trypanosoma cruzi coinfection in HIV-positive individuals outside endemic areas. Curr Opin Infect Dis 2014, 27:9-15.
12. Bern C Chagas disease in the immunosuppressed host. Curr Opin Infect Dis 2012, 25:450-457.
13. Shikanai-Yasuda MA, Carvalho NB Oral transmission of Chagas disease. Clin Infect Dis 2012, 54:845-852.
14. Gurevitz JM, Gaspe MS, Enriquez GF, Provecho YM, Kitron U, Gürtler RE Intensified surveillance and insecticide-based control of the Chagas disease vector Triatoma infestans in the Argentinean Chaco. PLoS Negl Trop Dis 2013, 7:e2158.
15. Bern C, Montgomery SP An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009, 49:e52-e54.
16. Navarro M, Navaza B, Guionnet A, López-Vélez R Chagas disease in Spain: need for further public health measures. PLoS Negl Trop Dis 2012, 6:e1962.
17. Howard EJ, Xiong X, Carlier Y, Sosa-Estani S, Buekens P Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysis. BJOG 2014, 121:22-33.
18. Martin-Davila P, Fortun J, Lopez-Velez R, et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 2008, 21:60-96.
19. Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL Chagas disease and the US blood supply. Curr Opin Infect Dis 2008, 21:476-482.
20. Villalba R, Fornes G, Alvarez MA, et al. Acute Chagas' disease in a recipient of a bone marrow transplant in Spain: case report. Clin Infect Dis 1992, 14:594-595.
21. Basile L, Carlier Y, Salamanca DD, et al. Working Group on Chagas Disease. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill 2011, 16. pii 19968.
22. Zulantay I, Apt W, Ramos D, et al. The epidemiological relevance of family study in Chagas disease. PLoS Negl Trop Dis 2013, 7:e1959.
23. Control of Chagas disease. Second report of the WHO Expert Committee. World Health Organ Tech Rep Sec 2002, 905:1-109. WHO Expert Committee.
24. Russomando G, de Tomassone MM, de Guillen I, et al. Treatment of congenital Chagas' disease diagnosed and followed up by the polymerase chain reaction. Am J Trop Med Hyg 1998, 59:487-491.
25. Brasil PE, De Castro L, Hasslocher-Moreno AM, Sangenis LH, Braga JU ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis. BMC Infect Dis 2010, 10:337.
26. Afonso AM, Ebell MH, Tarleton RL A systematic review of high quality diagnostic tests for Chagas disease. PLoS Negl Trop Dis 2012, 6:e1881.
27. Riera C, Verges M, Iniesta L, et al. Identification of a western blot pattern for the specific diagnosis of Trypanosoma cruzi infection in human sera. Am J Trop Med Hyg 2012, 86:412-426.
28. Chappuis F, Mauris A, Holst M, et al. Validation of a rapid immunochromatographic assay for diagnosis of Trypanosoma cruzi infection among Latin-American migrants in Geneva, Switzerland. J Clin Microbiol 2010, 48:2948-2952.
29. Holguin A, Norman F, Martin L, et al. Dried blood as an alternative to plasma or serum for Trypanosoma cruzi IgG detection in screening programs. Clin Vaccine Immunol 2013, 20:1197-1202.
30. Schijman AG, Bisio M, Orellana L, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis 2011, 5:e931.
31. Murcia L, Carrilero B, Muñoz MJ, Iborra MA, Segovia M Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country. J Antimicrob Chemother 2010, 65:1759-1764.
32. Moreira OC, Ramírez JD, Velázquez E, et al. Towards the establishment of a consensus real-time qPCR to monitor Trypanosoma cruzi parasitemia in patients with chronic Chagas disease cardiomyopathy: A substudy from the BENEFIT trial. Acta Tropica 2013, 125:23-31.
33. Coura JR, de Abreu LL, Pereira JB, Willcox HP [Morbidity in Chagas' disease. IV. Longitudinal study of 10 years in Pains and Iguatama, Minas Gerais, Brazil]. Mem Inst Oswaldo Cruz 1985, 80:73-80. [in Portuguese].
34. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006, 144:724-734.
35. Perez-Ayala A, Perez-Molina JA, Norman F, Monge-Maillo B, Faro MV, Lopez-Velez R Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis. Ann Trop Med Parasitol 2011, 105:25-29.
36. Andrade JP, Marin-Neto JA, Paola AA, et al. I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy. Arq Bras Cardiol 2011, 97:1-48. [in Portuguese].
37. Brazilian Consensus on Chagas disease. Rev Soc Bras Med Trop 2005, 38(suppl 3):7-29. Ministério da Saúde, Secretaria de Vigilância em SaúdeSecretaria de Vigilância em Saúde, [in Portuguese].
38. Coura JR, Borges-Pereira J Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz 2011, 106:641-645.
39. Perez-Ayala A, Perez-Molina JA, Norman F, et al. Chagas disease in Latin American migrants: a Spanish challenge. Clin Microbiol Infect 2011, 17:1108-1113.
40. Pinazo MJ, Guerrero L, Posada E, Rodriguez E, Soy D, Gascon J Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease. Antimicrob Agents Chemother 2013, 57:390-395.
41. Hasslocher-Moreno AM, do Brasil PE, de Sousa AS, Xavier SS, Chambela MC, Sperandio da Silva GM Safety of benznidazole use in the treatment of chronic Chagas' disease. J Antimicrob Chemother 2012, 67:1261-1266.
42. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis 2010, 51:e69-e75.
43. Pinazo MJ, Munoz J, Posada E, et al. Tolerance of benznidazole in treatment of chagas' disease in adults. Antimicrob Agents Chemother 2010, 54:4896-4899.
44. Wegner DH, Rohwedder RW The effect of nifurtimox in acute Chagas' infection. Arzneimittelforschung 1972, 22:1624-1635.
45. Streiger ML, del Barco ML, Fabbro DL, Arias ED, Amicone NA Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina. Rev Soc Bras Med Trop 2004, 37:365-375. [in Portuguese].
46. Rassi A, Amato Neto V, de Siqueira AF, et al. Treatment of chronic Chagas' disease with an association of nifurtimox and corticoid. Rev Soc Bras Med Trop 2002, 35:547-550. [in Portuguese].
47. Gorgolas M, Robles I, Cabello A, et al. The use of steroids to prevent cutaneous reactions to benznidazole in patients with Chagas disease. Pathog Glob Health 2013, 107:157-160.
48. Perez-Molina JA, Sojo-Dorado J, Norman F, et al. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment. Acta Trop 2013, 127:101-104.
49. Schijman AG, Altcheh J, Burgos JM, et al. Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother 2003, 52:441-449.
50. Altcheh J, Biancardi M, Lapena A, Ballering G, Freilij H Congenital Chagas disease: experience in the Hospital de Ninos, Ricardo Gutierrez, Buenos Aires, Argentina. Rev Soc Bras Med Trop 2005, 38:41-45. [in Portuguese].
51. Cancado JR Criteria of Chagas disease cure. Mem Inst Oswaldo Cruz 1999, 94:331-335.
52. de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996, 348:1407-1413.
53. Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis 2009, 3:e488.
54. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007, 40:1-10.
55. Viotti R, Vigliano C, Álvarez MG, et al. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl Trop Dis 2011, 5:e1314.
56. Perez-Molina JA, Perez-Ayala A, Moreno S, Fernandez-Gonzalez MC, Zamora J, Lopez-Velez R Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009, 64:1139-1147.
57. Marin-Neto JA, Rassi A, Morillo CA, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008, 156:37-43.
58. Carod-Artal FJ, Vargas AP, Falcao T Stroke in asymptomatic Trypanosoma cruzi-infected patients. Cerebrovasc Dis 2010, 31:24-28.
59. Rassi A, Rassi SG Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 2007, 115:1101-1108.
60. Lima-Costa MF, Peixoto SV, Ribeiro ALP Chagas disease and mortality in old age as an emerging issue: 10 year follow-up of the Bambuí population-based cohort study (Brazil). Int J Cardiol 2010, 145:362-363.
61. Actividad de Donación y Trasplante de Organos, Tejidos y Células, y Recomendaciones Aprobadas por el Consejo Iberoamericano de Donación y Trasplante. Newsletter 2013, 7:1-50. Red/Consejo Iberoamericano de Donación y Trasplante, Organización Nacional de TrasplantesOrganización Nacional de Trasplantes. http://www.ont.es/publicaciones/Documents/NEWSLETTER%20IBEROAMERICA%202013-1.pdf.
62. Miró JM, Blanes M, Norman F, Martín-Dávila P Infections in solid organ transplantation in special situations: HIV-infection and immigration. Enferm Infecc Microbiol Clín 2012, 30:76-85.
63. Duffy T, Bisio M, Altcheh J, et al. Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients. PLoS Negl Trop Dis 2009, 3:e419.
64. Fiorelli AI, Santos RH, Oliveira JL, et al. Heart transplantation in 107 cases of Chagas' disease. Transplant Proc 2011, 43:220-224.
65. Diez M, Favaloro L, Bertolotti A, et al. Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation. Am J Transplant 2007, 7:1633-1640.
66. Riarte A, Luna C, Sabatiello R, et al. Chagas' disease in patients with kidney transplants: 7 years of experience 1989-1996. Clin Infect Dis 1999, 29:561-567.
67. Altclas J, Sinagra A, Dictar M, et al. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 2005, 36:123-129.
68. Guiang KMU, Cantey P, Montgomery SP, et al. Reactivation of Chagas disease in a bone marrow transplant patient: case report and review of screening and management. Transpl Infect Dis 2013, 15:E264-E267.
69. Mattosinho-Franca LC, Lemos S Molestia de Chagas cronica asociada a leucemia linfatica. Ocorrencia de encefalite aguda como alteracao do estado inmunitario. Arq Neuropsiquiatr (Sao Paulo) 1969, 27:59-66.
70. Almeida HO, Tafuri WL, Bogliolo L, Cunha JC Parasitismo incomum do miocardio e do esofago em chagasico portador de doenca de Hodgkin e em uso de imunossupressores. Rev Soc Bras Med Trop 1974, 8:117-121.
71. Rivero I, Boris E, Moravenik M, Morales JA, Gomez ME, de Rosas JM Acute leukaemia and Chagas' disease. Medicina (B Aires) 1975, 35:73-78. (in Spanish).
72. Kohl S, Pickering LK, Frankel LS, Yaeger RG Reactivation of Chagas' disease during therapy of acute lymphocytic leukemia. Cancer 1982, 50:827-828.
73. Fontes Rezende RE, Lescano MA, Zambelli Ramalho LN, et al. Reactivation of Chagas' disease in a patient with non-Hodgkin's lymphoma: gastric oesophageal and laryngeal involvement. Trans R Soc Trop Med Hyg 2006, 100:74-78.
74. Pinazo M-J, Espinosa G, Cortes-Lletget C, et al. Immunosuppression and Chagas disease: a management challenge. PLoS Negl Trop Dis 2013, 7:e1965.
75. Burgos LG, Ortiz BD, Canese A, Ojeda A, Melo M Reactivation of Chagas disease by immunosuppressive therapy in a patient with systemic lupus erythematosus: report of an exceptional case. Am J Dermatopathol 2012, 34:e84-e89.
76. dos Santos-Neto LL, Polcheira MF, Castro C, Lima RA, Simaan CK, Correa-Lima FA Trypanosoma cruzi high parasitemia in patient with systemic lupus erythematosus. Rev Soc Bras Med Trop 2003, 36:613-615. [in Portuguese].
77. Pinto AYdN, Valente VdC, Coura JR, et al. Clinical follow-up of responses to treatment with benznidazol in Amazon: a cohort study of acute Chagas disease. PLoS One 2013, 8:e64450.
78. Solari A, Ortíz S, Soto A, et al. Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR. J Antimicrob Chemother 2001, 48:515-559.
79. Britto CC Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations. Mem Inst Oswaldo Cruz 2009, 104:122-135.
80. Molina I, Gómez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas disease. N Engl J Med 2014, 370:1899-1908.
81. Murta SMF, Gazzinelli RT, Brener Z, Romanha AJ Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol 1998, 93:203-214.
82. Tornheim JA, Lozano Beltran DF, Gilman RH, et al. Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia. PLoS Negl Trop Dis 2013, 7:e2407.
83. Moreno M, D'Avila DA, Silva MN, et al. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Mem Inst Oswaldo Cruz 105: 918-24.
84. Mejia AM, Hall BS, Taylor MC, et al. Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population. J Infect Dis 2012, 206:220-228.
85. Martinez I, Nogueda B, Martinez-Hernandez F, Espinoza B Microsatellite and mini-exon analysis of Mexican human DTU I Trypanosoma cruzi strains and their susceptibility to nifurtimox and benznidazole. Vector Borne Zoonotic Dis 2013, 13:181-187.
86. Villarreal D, Barnabe C, Sereno D, Tibayrenc M Lack of correlation between in vitro susceptibility to benznidazole and phylogenetic diversity of Trypanosoma cruzi, the agent of Chagas disease. Exp Parasitol 2004, 108:24-31.
87. Cencig S, Coltel N, Truyens C, Carlier Y. Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome. PLoS Negl Trop Dis 5: e1216.
88. Rassi A, Luquetti AO, Rassi A, et al. Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. Am J Trop Med Hyg 2007, 76:58-61.
89. Perez-Mazliah DE, Alvarez MG, Cooley G, et al. Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. J Antimicrob Chemother 2013, 68:424-437.
90. "E1224-results of proof-of-concept clinical trial in patients with chronic indeterminate Chagas disease". 2014 [cited 17/03/2014] DNDi, (accessed Oct 14, 2014). http://www.dndi.org/media-centre/press-releases/354-media-centre/press-releases/1700-e1224.html.
91. Bustamante JM, Craft JM, Crowe BD, Ketchie SA, Tarleton RL New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis 2014, 209:150-162.